Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Ph
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-1.02||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||5.98%||Sales Growth - Q/Q||-11.95%||P/E||-86.75|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-4.46%||ROE||-6.74%||ROI||-5.17%|
|Current Ratio||4.98||Quick Ratio||4.25||Long Term Debt/Equity||0.54||Debt Ratio||0.13|
|Gross Margin||82.59%||Operating Margin||-16.48%||Net Profit Margin||-20.35%||Dividend Payout Ratio|
|Cash From Financing Activities||914.79 M||Cash From Investing Activities||-750.87 M||Cash From Operating Activities||-137.81 M||Gross Profit||170.45 M|
|Net Profit||-67.5 M||Operating Profit||-66.02 M||Total Assets||3.66 B||Total Current Assets||1.52 B|
|Total Current Liabilities||305.51 M||Total Debt||655.49 M||Total Liabilities||1.23 B||Total Revenue||203.26 M|
|High 52 week||106.07||Low 52 week||76.01||Last close||76.99||Last change||0.13%|
|RSI||33.73||Average true range||2.22||Beta||1.08||Volume||685.95 K|
|Simple moving average 20 days||-3.78%||Simple moving average 50 days||-6.13%||Simple moving average 200 days||-13.32%|
|Performance Week||-1.09%||Performance Month||-6.93%||Performance Quart||-6.6%||Performance Half||-18.34%|
|Performance Year||-25.48%||Performance Year-to-date||-9.58%||Volatility daily||1.48%||Volatility weekly||3.31%|
|Volatility monthly||6.78%||Volatility yearly||23.47%||Relative Volume||211.9%||Average Volume||1.29 M|
|New High||New Low|
2019-11-15 04:00:00 | BioMarin Can Trade Sideways in the Near-Term, Use It as a Buying Opportunity
2019-11-12 11:37:00 | Buy Big Biotech — But Not Gilead, Analyst Says
2019-11-12 10:32:00 | The Winds Have Changed for BioMarin
2019-11-12 09:30:02 | REGN or BMRN: Which Is the Better Value Stock Right Now?
2019-11-12 08:30:00 | BioMarin to Participate in Jefferies London Healthcare Conference on November 21, 2019
2019-11-08 14:33:07 | Sarepta SRPT Q3 Loss Widens Y/Y, Revenues Beat Estimates
2019-11-08 10:02:02 | After son’s rare disease diagnosis, father finds hope through film festival
2019-11-06 16:05:00 | BioMarin to Highlight Innovative Development Pipeline at R&D Day on November 14th
2019-10-30 09:23:01 | Can The Uptrend Continue for BioMarin Pharmaceutical?
2019-10-29 09:00:01 | BioMarin BMRN Upgraded to Buy: What Does It Mean for the Stock?
2019-10-24 12:50:04 | BioMarin's BMRN Earnings & Revenues Beat Estimates in Q3
2019-10-24 10:03:00 | BioMarin Stock Rises on Earnings Beat
2019-10-24 09:30:01 | HZNP or BMRN: Which Is the Better Value Stock Right Now?
2019-10-24 05:56:50 | Edited Transcript of BMRN earnings conference call or presentation 23-Oct-19 8:30pm GMT
2019-10-23 17:55:09 | BioMarin Pharmaceutical BMRN Surpasses Q3 Earnings and Revenue Estimates
2019-10-23 16:05:00 | BioMarin Announces Third Quarter 2019 Financial Results
2019-10-22 11:32:03 | Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More
2019-10-19 09:14:52 | BioMarin Pharmaceutical NASDAQ:BMRN Is Carrying A Fair Bit Of Debt
2019-10-18 18:23:43 | BioMarin Pharmaceutical Inc. BMRN: Hedge Funds Fumbled the Ball
2019-10-17 10:41:00 | 4 Biotech Stocks That Are Set to Rally, Analyst Says
2019-10-16 10:33:02 | BioMarin Pharmaceutical BMRN Reports Next Week: Wall Street Expects Earnings Growth
2019-10-07 08:31:00 | BioMarin Promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer
2019-09-30 14:52:13 | Investors flee Biotech ETFs as they Lag Bull Market
2019-09-30 11:00:00 | Healthcare: Political Uncertainties Have Weighed on the Sector
2019-09-27 21:39:00 | Biotech Roundtable: How to Invest in Medicine’s Future
2019-09-20 13:10:14 | Gilead, AbbVie Are Innovative, but May Be Underappreciated
2019-09-15 15:28:47 | Stocks That Fell to 3-Year Lows in the Week of Sept. 13
2019-09-13 08:12:56 | Is BioMarin Pharmaceutical Inc. NASDAQ:BMRN Overpaying Its CEO?
2019-08-31 09:31:01 | BioMarin BMRN Down 7.3% Since Last Earnings Report: Can It Rebound?
2019-08-14 12:06:57 | Is BioMarin Pharmaceutical Inc. NASDAQ:BMRN Trading At A 31% Discount?
2019-08-08 16:29:20 | 6 Underperforming Stocks in Gurus' Portfolios
2019-08-08 10:33:02 | Sarepta SRPT Q2 Loss Widens Y/Y, Golodirsen Nears Approval
2019-08-06 10:45:00 | BioMarin's Roller Coaster Continues
2019-08-03 08:54:04 | Edited Transcript of BMRN earnings conference call or presentation 1-Aug-19 8:30pm GMT
2019-08-02 11:23:36 | Biomarin Pharmaceutical Inc BMRN Q2 2019 Earnings Call Transcript
2019-08-02 10:52:02 | BioMarin BMRN Shares Down on Q1 Earnings & Sales Miss
2019-08-02 09:15:00 | BioMarin Stock Dropped After Hours on Weak Earnings, but Analysts Aren’t Worried
2019-08-01 18:05:10 | BioMarin Pharmaceutical BMRN Lags Q2 Earnings and Revenue Estimates